(Q42664678)

4 November 2017

title

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective (English)

1 reference

4 November 2017

1 reference

Madlaina Costa-Scharplatz

1

1 reference

4 November 2017

Krishnan Ramanathan

2

1 reference

4 November 2017

Tony Frial

3

1 reference

4 November 2017

Bruce Beamer

4

1 reference

4 November 2017

Sanjay Gandhi

5

1 reference

4 November 2017

publication date

1 July 2008

1 reference

4 November 2017

published in

Clinical Therapeutics

1 reference

4 November 2017

volume

30

1 reference

4 November 2017

issue

7

1 reference

4 November 2017

page(s)

1345-1357

1 reference

Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Hypertriglyceridemia: its etiology, effects and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980061-6

7 January 2021

10.1016/S0149-2918(08)80061-6

Identifiers

DOI

1 reference

4 November 2017

1 reference